Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Mar. 31, 2017
Current assets:
Cash	$ 128,873	$ 180,838
Prepaid expenses and other current assets	5,279	3,221
Income tax receivable	607	105
Total current assets	134,759	184,164
Deferred tax assets	0	208
Furniture and equipment, net	1,120	906
Other assets	2,098	0
Total assets	137,977	185,278
Current liabilities:
Accounts payable	2,091	3,329
Accrued expenses	20,953	11,978
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc.	3,683	3,030
Total current liabilities	26,727	18,337
Takeda warrant liability	0	52
Deferred rent	372	113
Deferred interest payable	105	0
Long-term debt	28,575	0
Total liabilities	55,779	18,502
Commitments and contingencies (Note 8)
Shareholders’ equity:
Common shares, par value $0.000017727 per share, 564,111,242 shares authorized, 60,989,395 and 60,275,757 issued and outstanding at December 31, 2017 and March 31, 2017, respectively	1	1
Common shares subscribed	(1)	(1)
Additional paid-in capital	262,510	251,733
Accumulated other comprehensive (loss) income	(91)	140
Accumulated deficit	(180,221)	(85,097)
Total shareholders’ equity	82,198	166,776
Total liabilities and shareholders’ equity	$ 137,977	$ 185,278